Vishva Mitra Dixit (born ) is a Kenyan-born American physician, biomedical researcher, and biotechnology executive whose discoveries transformed the modern understanding of programmed cell death, innate immunity, and inflammatory signaling. He is Vice President of Early Discovery Research at Genentech and is internationally recognized for elucidating the molecular mechanisms of apoptosis, identifying the signaling pathways of death receptors, discovering critical components of the caspase cascade, and pioneering research on inflammasomes, pyroptosis, necroptosis, and inflammatory cell death. His work has reshaped molecular and cellular biology and has had far-reaching implications for cancer biology, immunology, infectious diseases, neurodegeneration, and drug discovery.
Dixit has authored more than 300 scientific publications, many of which focuses on molecular biology and immunology. His discoveries established entirely new paradigms for understanding how cells undergo programmed death and how the innate immune system detects pathogens and tissue injury. Among his contributions are the identification of caspase-3 and caspase-8 as central regulators of apoptosis, elucidation of death receptor signaling through adaptor proteins and protease cascades, discovery of the noncanonical inflammasome pathway mediated by caspase-11, identification of Gasdermin D as the molecular executor of pyroptosis, characterization of RHIM-mediated signaling in necroptosis, and the demonstration that NINJ1 controls plasma membrane rupture during inflammatory cell death.
He has received awards including the Vilcek Prize in Biomedical Science, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, the Dr. A.H. Heineken Prize for Medicine, the Dawson Prize in Genetics, the Clowes Award of the American Association for Cancer Research, and the Gutenberg Prize.
He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and a foreign member of The Royal Society. His honours include the Dr. A.H. Heineken Prize for Medicine, the Vilcek Prize, the William B. Coley Award, and the Gutenberg Research Award. In 2026, he was elected to the American Philosophical Society.
Early life and education Vishva Dixit was born in Kenya in 1956. His parents were both physicians, working for the British colonial authorities. Dixit was interested in science from an early age, and his parents encouraged him to pursue a career in medicine. He graduated in 1980 from the University of Nairobi with a Bachelor of Medicine and Bachelor of Surgery, becoming a medical doctor.
Career
Academia After earning his M.D. from the University of Nairobi in 1981, Dixit moved to the United States for postgraduate training in laboratory medicine and pathology at Washington University School of Medicine. Between 1982 and 1986 he simultaneously served as a postdoctoral fellow and research associate in the Department of Biological Chemistry under the mentorship of biochemist William A. Frazier, where he investigated thrombospondins and extracellular matrix proteins involved in vascular biology and tumor progression. These early studies established him as an emerging investigator in molecular pathology and provided the biochemical foundation for his later discoveries in apoptosis and inflammatory signaling.
In 1986, Dixit joined the faculty of the University of Michigan Medical School as an Assistant Professor of Pathology. He was promoted to Associate Professor in 1991 and Full Professor in 1995. During his tenure at Michigan, he shifted his research from vascular biology toward the molecular mechanisms of programmed cell death. His laboratory became one of the world's leading centers for apoptosis research, publishing a series of landmark papers that identified critical components of death receptor signaling, including FADD, caspase-3, and caspase-8, discoveries that fundamentally altered the understanding of receptor-mediated signal transduction and programmed cell death.
He was appointed Vice President of Molecular Oncology in 2003 and, in 2005, became Vice President of Early Discovery Research and Senior Fellow in Physiological Chemistry. In these roles, he has led multidisciplinary research programs integrating molecular biology, immunology, genetics, structural biology, chemistry, and translational medicine.
He has served on advisory and review panels for organizations including the Howard Hughes Medical Institute, the Gates Foundation, and the Keystone Symposia on Molecular and Cellular Biology, while also contributing to the editorial boards of numerous leading scientific journals.
A 2022 profile published by the Proceedings of the National Academy of Sciences described Dixit as one of the foremost investigators in cell death and innate immunity, highlighting his ability to combine curiosity-driven basic science with discoveries that have inspired therapeutic development.
Genentech In 1997, Dixit joined Genentech as Director of Molecular Oncology. In 2009 he led the Department of Physiological Chemistry. As of 2016 he held the position of Vice President of Discovery Research, and oversaw Genentech's postdoctoral program.
Under Dixit, Genentech became widely recognized as a leading center for research into inflammatory signaling pathways, programmed cell death, inflammasome biology, and innate immunity. His laboratory made contributions to elucidating the molecular mechanisms governing apoptosis, necroptosis, pyroptosis, and inflammatory caspase signaling, discoveries that have informed drug development programs targeting autoimmune diseases, inflammatory disorders, septic shock, infectious diseases, metabolic disorders, neurodegenerative diseases, liver disease, and cancer immunotherapy.
Dixit also played a major role in fostering Genentech's scientific culture, mentoring generations of graduate students, postdoctoral fellows, and early-career investigators. His laboratory became known for combining rigorous mechanistic biology with clinical relevance, reflecting Genentech's longstanding emphasis on investigator-driven basic research within an industrial setting. During his nearly three decades at the company, he authored numerous highly cited publications in leading scientific journals, including Nature, Science, Cell, Nature Immunology, Nature Cell Biology, and Molecular Cell, reinforcing his position as one of the biotechnology industry's most influential research scientists.
Notable research discoveries As one of the world's most cited scientists, some of Dixit's publications have garnered more than 2,000 citations. He was the second most highly cited scientist in the world in 1996. His lab's discovery of MYD88 (25) as a central conduit for signals emanating from the interleukin-1 receptor is considered as one of the "Pillars in Immunology" by the Journal of Immunology.
Dixit's papers, including his work on apoptosis and inflammation, have been designated "hot papers" on multiple occasions by The Scientist. His research on apoptosis (programmed cell death) is now commonly found in introductory textbooks in both biology and medicine.
Early research on thrombospondin While at the University of Michigan, he received funding from the National Institutes of Health to support research into thrombospondin, as his laboratory had shown this protein had a role in promoting cancer metastases.
Caspases and apoptosis In 1991, an article in Scientific American inspired Dixit to study how tumor necrosis factors, which are responsible for the regulation of immune cells, trigger inflammation and cell death.
In 1996, he published the first evidence that death receptors engaged a mammalian deathase, a molecular scissors (protease) that cleaves proteins. His team's work on death receptor-induced apoptosis was notable, for prior to that time, cell surface receptors were thought to signal by functioning as ion channels or altering intracellular phosphorylation. Death receptors, however, signal by a different mechanism—activation of a death protease.
Collaborating with Guy Salvesen's group at the Burnham Institute, Dixit's group proposed the model of proximity-induced autoactivation in 1998 to explain how the first proteolytic signal is generated by caspase precursors recruited to death receptors.
RIP kinases, NF-κB signaling and necroptosis At Genentech, Dixit formed a team with the goal of unraveling the complex interplay between cell death and inflammation at the molecular level. During his tenure, he has worked on the innate immune system, particularly its role in orchestrating an inflammatory response to fight pathogens and cancer.
In 1999, his team discovered RIPK2 and RIPK3, which later were shown to be key mediators of NF-κB signaling and necroptosis, respectively. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, and improper immune development.
Dixit's work contributed to the discovery of a core complex composed of three proteins that enabled antigen receptors to activate the canonical NF-κB pathway: CARD11, BCL10 and MALT1/paracaspase. Furthermore, he postulated a protease activity for MALT1, which plays a role in T cell activation and MALT lymphomas. His team described the family of metacaspase proteases in plants in a paper published in 2000.
In a series of papers between 2016 and 2020, Dixit and his colleagues at Genentech also worked out the complex molecular mechanisms that regulate activity of caspase-8, OTULIN, RIPK1, RIPK3 and other proteins that modulate inflammation, apoptosis and necroptosis signaling by death receptors and TLRs.
Inflammasomes and pyroptosis By 2002, Dixit was among the first scientists to demonstrate that pro-inflammatory caspases are part of a molecular complex named inflammasomes that are integral to the proper functioning of the innate immune system. In particular, he defined regulatory components upstream of caspase-1 that proteolytically activate the pro-inflammatory cytokines interleukin-1beta and interleukin-18.
In 2004 and 2006, Dixit provided unequivocal genetic evidence by identifying the NOD-like receptors NLRP3 and NLRC4 as proximal components of inflammasomes responsible for caspase-1 activation.
More specifically, the intracellular protein NLRC4 was identified as a sensor for Salmonella that triggered assembly of an inflammasome complex. NLRP3 and the inflammasome adaptor ASC, on the other hand, were found to be required for activation of the inflammasome by diverse pathogenic agents, including microbial toxins, and Gram-positive bacteria such as Staphylococcus aureus or Listeria monocytogenes.
In 2009, his group followed up on these findings with the discovery of the first small molecule inhibitors of the NLRP3 inflammasome. Derived analogs of this sulfonylurea class of compounds are currently in clinical development for inflammatory and neurodegenerative diseases.
Dixit's team discovered the non-canonical inflammasome pathway and its critical role in mediating lethal systemic inflammation in response to Gram-negative pathogens, detailed in three papers in 2011, 2013, and 2015.
The 2011 paper showed that mice lacking the gene that encodes caspase-1 also carry a mutation in a neighboring caspase gene, caspase-11 (caspase-4 in humans), which is responsible for many of the effects previously attributed to caspase-1, including sensitivity to sepsis.